Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma.

By L. Benboubker, M. Dimopoulos, A. Dispenzieri, J. Catalano, A. Belch, M. Cavo, A. Pinto, K. Weisel, H. Ludwig, N. Bahlis and 24 more. New England Journal of Medicine, 2014

759 citations recorded by the source corpus.

Subfields: Hematology, Molecular Biology, Oncology

View Paper: https://www.semanticscholar.org/paper/941a39d22bac908ea3e99ce392809625fdf5ed2b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Hematology

1. S. Rajkumar

In Molecular Biology

1. P. Richardson
2. J. Adams
3. S. Rajkumar

In Oncology

1. S. Rajkumar
2. J. Adams

Citations in the corpus

• Lenalidomide, Bortezomib, and Dexamethasone with Transplantation in Myeloma. (2017, background): “t(4;14) or t(14;16) translocation or 17p deletion 44/256 46/259”
• Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016, neutral): “Back pain 87 (24) 3 (<1) 0 62 (17) 9 (3) 0”